COSCIENS Biopharma (CSCI) Competitors $3.16 +0.02 (+0.51%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock CSCI vs. KLTO, RNXT, BTAI, ESLA, EGRX, SCYX, CLSD, SNYR, AKTX, and MURAShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Klotho Neurosciences (KLTO), RenovoRx (RNXT), BioXcel Therapeutics (BTAI), Estrella Immunopharma (ESLA), Eagle Pharmaceuticals (EGRX), SCYNEXIS (SCYX), Clearside Biomedical (CLSD), Synergy CHC (SNYR), Akari Therapeutics (AKTX), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. COSCIENS Biopharma vs. Its Competitors Klotho Neurosciences RenovoRx BioXcel Therapeutics Estrella Immunopharma Eagle Pharmaceuticals SCYNEXIS Clearside Biomedical Synergy CHC Akari Therapeutics Mural Oncology COSCIENS Biopharma (NASDAQ:CSCI) and Klotho Neurosciences (NASDAQ:KLTO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Which has preferable valuation and earnings, CSCI or KLTO? Klotho Neurosciences has lower revenue, but higher earnings than COSCIENS Biopharma. Klotho Neurosciences is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOSCIENS Biopharma$9.59M1.04-$15.31M-$6.01-0.53Klotho NeurosciencesN/AN/A-$6.15M-$0.45-1.61 Is CSCI or KLTO more profitable? Klotho Neurosciences has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -199.55%. COSCIENS Biopharma's return on equity of -149.49% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets COSCIENS Biopharma-199.55% -149.49% -54.80% Klotho Neurosciences N/A -325.88%-242.15% Which has more volatility & risk, CSCI or KLTO? COSCIENS Biopharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Klotho Neurosciences has a beta of 10.9, suggesting that its share price is 990% more volatile than the S&P 500. Do institutionals and insiders have more ownership in CSCI or KLTO? 0.7% of COSCIENS Biopharma shares are owned by institutional investors. Comparatively, 20.1% of Klotho Neurosciences shares are owned by institutional investors. 0.1% of COSCIENS Biopharma shares are owned by insiders. Comparatively, 26.7% of Klotho Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer CSCI or KLTO? In the previous week, COSCIENS Biopharma and COSCIENS Biopharma both had 1 articles in the media. COSCIENS Biopharma's average media sentiment score of 1.88 beat Klotho Neurosciences' score of 1.87 indicating that COSCIENS Biopharma is being referred to more favorably in the media. Company Overall Sentiment COSCIENS Biopharma Very Positive Klotho Neurosciences Very Positive SummaryKlotho Neurosciences beats COSCIENS Biopharma on 6 of the 11 factors compared between the two stocks. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.95M$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-0.5321.1531.3126.63Price / Sales1.04383.94459.79120.56Price / CashN/A44.4437.7659.36Price / Book1.408.0810.026.70Net Income-$15.31M-$54.08M$3.27B$265.68M7 Day Performance19.82%2.44%3.26%3.46%1 Month Performance-17.17%3.56%4.45%1.11%1 Year Performance-16.73%18.78%44.34%24.00% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$3.16+0.5%N/AN/A$9.95M$9.59M-0.5320KLTOKlotho NeurosciencesN/A$0.78-0.2%N/AN/A$36.21MN/A-1.74N/APositive NewsGap UpRNXTRenovoRx3.0504 of 5 stars$0.92-2.0%$7.25+686.8%-3.7%$34.38M$40K-2.426Analyst ForecastGap UpBTAIBioXcel Therapeutics4.5322 of 5 stars$4.92-13.2%$39.75+707.9%-62.4%$34.34M$2.27M-0.3990Trending NewsAnalyst DowngradeESLAEstrella Immunopharma3.1395 of 5 stars$0.92+0.1%$16.00+1,639.1%-15.3%$34.08MN/A-3.54N/AEGRXEagle PharmaceuticalsN/A$2.60-18.8%N/A-33.0%$33.77M$257.55M0.00100Gap DownSCYXSCYNEXIS1.1304 of 5 stars$0.79-1.6%N/A-43.6%$33.65M$3.75M-1.9760CLSDClearside Biomedical2.6801 of 5 stars$0.40-5.6%$4.20+944.8%-61.7%$33.44M$1.66M-1.0930Positive NewsSNYRSynergy CHC4.3679 of 5 stars$3.28-5.7%$10.00+204.9%N/A$32.86M$34.83M8.6340AKTXAkari Therapeutics3.0575 of 5 stars$0.99-0.9%$5.00+404.3%-77.4%$32.18MN/A0.009Positive NewsMURAMural Oncology2.7525 of 5 stars$1.80-1.1%$12.00+566.7%-37.4%$31.53MN/A-0.21119 Related Companies and Tools Related Companies KLTO Competitors RNXT Competitors BTAI Competitors ESLA Competitors EGRX Competitors SCYX Competitors CLSD Competitors SNYR Competitors AKTX Competitors MURA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSCI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access